Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy

Nat Rev Endocrinol. 2013 Feb;9(2):70-2. doi: 10.1038/nrendo.2012.250. Epub 2013 Jan 8.

Abstract

Neuroendocrine tumours are a heterogeneous group of neoplasms with various clinical presentations, growth rates and responses to available therapies. Studies published in 2012 have provided insights into tumour-cell signalling that will increase our knowledge of tumour biology and molecular genetics, making it possible to personalize patient care.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic
  • Everolimus
  • Humans
  • Neuroendocrine Tumors / drug therapy
  • Neuroendocrine Tumors / genetics
  • Neuroendocrine Tumors / metabolism*
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / metabolism*
  • Precision Medicine
  • Receptor, Fibroblast Growth Factor, Type 4 / genetics
  • Signal Transduction*
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use

Substances

  • Antineoplastic Agents
  • Everolimus
  • FGFR4 protein, human
  • Receptor, Fibroblast Growth Factor, Type 4
  • Sirolimus